DexCom面临集体诉讼, 指控未经批准更改其葡萄糖监测器, 危害安全和误导投资者。 DexCom faces a class action lawsuit for unauthorized changes to its glucose monitors, allegedly compromising safety and misleading investors.

对DexCom公司提起了集体诉讼,指控该公司在2024年1月至2025年9月期间未经林业发展局批准擅自改变其G6和G7甘蔗糖监测器的设计,损害装置的可靠性和准确性,造成健康风险,误导投资者对安全、业绩和监管风险的看法。 A class action lawsuit has been filed against DexCom, Inc. alleging the company made unauthorized design changes to its G6 and G7 glucose monitors without FDA approval between January 2024 and September 2025, compromising device reliability and accuracy, posing health risks, and misleading investors about safety, performance, and regulatory risks. DexCom公司声称DexCom低估了这些问题,并歪曲了G7公司的改进,使公司面临更大的监督和财政损害。 The suit claims DexCom downplayed these issues and misrepresented the G7’s improvements, exposing the company to increased scrutiny and financial harm. 在此期间蒙受损失的投资者可能有资格加入该案,截止日期为2025年12月26日,以申请主要原告地位。 Investors who suffered losses during the period may be eligible to join the case, with a deadline of December 26, 2025, to request lead plaintiff status. 参与是免费的,没有预付费用。 Participation is free, with no upfront fees.